Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment
NCT00703118 is registered in ClinicalTrials.gov with Tibotec BVBA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment
- Lead sponsor
- Tibotec BVBA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- July 31, 2010
- Enrollment
- 663 (actual)
- Sites
- 91
Conditions
As the registry lists them; a condition with its own page is linked.